758 results match your criteria Thrombocytosis Secondary


Clustering of blood cell count abnormalities and future risk of death.

Eur J Clin Invest 2021 May 7:e13562. Epub 2021 May 7.

Department of Clinical Sciences, Lund University, Malmö, Sweden.

Background: The identification of novel predictors of poor outcome may help stratify cardiovascular risk. Aim was to evaluate the individual contribution of blood cell count parameters, as well as their clustering, on the risk of death and cardiovascular events over the long term in the population-based Malmö Diet and Cancer Study cohort.

Methods: In 30,447 individuals (age 57 ± 8 years), we assessed the incidence of all-cause death (primary endpoint) and major adverse cardiovascular events (MACE, secondary outcome measure) according to absence or presence of one, two and three factors at baseline out of the following: anaemia, leukocytosis and thrombocytosis. Read More

View Article and Full-Text PDF

Pseudohyperkalaemia in essential thrombocytosis: an important clinical reminder.

Endocrinol Diabetes Metab Case Rep 2021 Apr 1;2021. Epub 2021 Apr 1.

Mater Dei Hospital of Malta, Department of Medicine, Msida, Malta.

Summary: An 82-year-old female was admitted to a general hospital due to progressive bilateral lower limb weakness. A T8-T9 extramedullary meningioma was diagnosed by MRI, and the patient was referred for excision of the tumour. During the patient's admission, she was noted to have persistent hyperkalaemia which was refractory to treatment. Read More

View Article and Full-Text PDF

Low-Risk Essential Thrombocythemia: A Comprehensive Review.

Hemasphere 2021 Feb 27;5(2):e521. Epub 2021 Jan 27.

Haematopathology and Oncology Diagnostics Service/Department of Haematology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.

Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm characterized by a persistently elevated platelet count in the absence of a secondary cause. The clinical consequences of uncontrolled thrombocytosis can include both thrombosis and hemorrhage. Patients with features conferring a "high risk" of vascular events benefit from reduction of the platelet count through cytoreductive therapy. Read More

View Article and Full-Text PDF
February 2021

Covid-19 and diabetes in primary care - How do hematological parameters present in this cohort?

Expert Rev Endocrinol Metab 2021 Apr 5:1-7. Epub 2021 Apr 5.

Institute of Sport Sciences, Otto-von-Guericke University, Magdeburg, Germany.

: Changes in hematological parameters are becoming evident as important early markers of COVID-19. Type 2 Diabetes Mellitus (T2DM) has been shown to be associated with increased severity of COVID-19. In this study, we aim to explore the various hematological variables in COVID-19 positive patients with T2DM, so as to act early and improve patient outcomes. Read More

View Article and Full-Text PDF

Clinical and Molecular Attributes of Patients With BCR/ABL1-negative Myeloproliferative Neoplasms in India: Real-world Data and Challenges.

Clin Lymphoma Myeloma Leuk 2021 Feb 23. Epub 2021 Feb 23.

Molecular Genetics, Dayanand Medical College and Hospital, Ludhiana, Punjab, India.

Introduction: Classic BCR/ABL1-negative myeloproliferative neoplasms (MPNs) are characterized by clinical and genetic heterogeneity and include 4 distinct constituents. Very little data on clinical presentation and epidemiology of the same is available from the Indian setting.

Patients And Methods: Patients referred to Hematology-Oncology from January 2018 to August 2020 with suspected MPNs were included in the analysis and prospectively followed-up. Read More

View Article and Full-Text PDF
February 2021

Thrombocytosis in children and adolescents-classification, diagnostic approach, and clinical management.

Ann Hematol 2021 Mar 12. Epub 2021 Mar 12.

Department of Pediatric Oncology, Hematology and Immunology and Hopp Children's Cancer Research Center (KiTZ), Heidelberg University and German Cancer Research Center (DKFZ), Heidelberg, Germany.

Secondary thrombocytosis is a frequent secondary finding in childhood infection and inflammation. Primary hereditary thrombocytosis may be caused by germline mutations within the genes encoding key regulators of thrombopoiesis, i.e. Read More

View Article and Full-Text PDF

Polycythemia Vera and Essential Thrombocythemia Patients Exhibit Unique Serum Metabolic Profiles Compared to Healthy Individuals and Secondary Thrombocytosis Patients.

Cancers (Basel) 2021 Jan 27;13(3). Epub 2021 Jan 27.

Drug Discovery Unit, Instituto de Investigación Sanitaria La Fe, 46026 Valencia, Spain.

Most common myeloproliferative neoplasms (MPNs) include polycythemia vera (PV) and essential thrombocythemia (ET). Accurate diagnosis of these disorders remains a clinical challenge due to the lack of specific clinical or molecular features in some patients enabling their discrimination. Metabolomics has been shown to be a powerful tool for the discrimination between different hematological diseases through the analysis of patients' serum metabolic profiles. Read More

View Article and Full-Text PDF
January 2021

Thrombocytosis during Stable State Predicts Mortality in Bronchiectasis.

Ann Am Thorac Soc 2021 Jan 28. Epub 2021 Jan 28.

University of Dundee, 3042, Dundee, Dundee, United Kingdom of Great Britain and Northern Ireland.

Rationale: Although platelets are considered key inflammatory mediators in respiratory diseases, their role in bronchiectasis has not been fully explored.

Objectives: We hypothesized that thrombocytosis in stable state may be associated with bronchiectasis severity and worse clinical outcomes.

Methods: Bronchiectasis patients have been enrolled from 10 centers in Europe and Israel, with platelet count recorded during stable state. Read More

View Article and Full-Text PDF
January 2021

Evaluation of angiogenic signaling molecules associated with reactive thrombocytosis in an iron-deficient rat model.

Pediatr Res 2021 Jan 19. Epub 2021 Jan 19.

Department of Pediatrics, Division of Hematology/Oncology, University of Illinois College of Medicine Peoria, Peoria, IL, USA.

Background: Iron deficiency anemia (IDA)-induced reactive thrombocytosis can occur in children and adults. The underlying mechanism for this phenomenon is indeterminate. Traditional cytokines such as thrombopoietin (TPO), interleukin-6 (IL-6), and IL-11 involved in megakaryopoiesis have not been shown to be the cause. Read More

View Article and Full-Text PDF
January 2021

[Development of skin squamous cell carcinoma on the scalp in a hydroxycarbamide-treated polycythemia vera patient].

Rinsho Ketsueki 2020 ;61(12):1670-1672

Department of Hematology/Oncology, University of Yamanashi.

Hydroxycarbamide is a widely used cytoreductive agent for treating polycythemia vera and essential thrombocythemia. Although hydroxycarbamide is usually well tolerated by most patients for long periods, some patients experience mucosal or cutaneous adverse events. Furthermore, a series of case report have indicated an association of hydroxycarbamide use with the development of non-melanoma skin cancer, especially in western countries. Read More

View Article and Full-Text PDF
February 2021

CONTRIBUTION OF THE G1691A ALLELE CARRYING OF THE COAGULATION FACTOR V GENE TO THE DEVELOPMENT OF THROMBOSES IN RADIATION-EXPOSED PATIENTS WITH REACTIVE CHANGES IN PERIPHERAL BLOOD.

Probl Radiac Med Radiobiol 2020 Dec;25:502-515

State Institution «National Research Center for Radiation Medicine of National Academy of Medical Sciences of Ukraine», 53 Yuriia Illienka St., Kyiv, 04050, UkraineShupyk National Medical Academy of Postgraduate Education, 9 Dorohozhytska St., Kyiv, 04112, Ukraine.

Thrombosis triggers, in addition to «classic» risk factors (RFs) of cardiovascular events, includes the reactive changesof peripheral blood (RCPB), markers of the hereditary thrombophilia and radiation anamnesis. However, results ofmost studies suggest the «classic» RFs are able to neutralize the prothrombogenic potential of the hereditary thrombophilia and other, less powerful predictors of thrombosis.

Objective: to determine the influence of the G1691A allele of the proaccelerin gene carrying to the thrombosis development, taking into account the vascular type of their occurrence, the presence of RFs in individuals with RCPB (reactive leukocytosis and thrombocytosis, and secondary erythrocytosis), as well as with and without radiation anamnesis. Read More

View Article and Full-Text PDF
December 2020

Erythrocytosis in the general population: clinical characteristics and association with clonal hematopoiesis.

Blood Adv 2020 12;4(24):6353-6363

Department of Hematology.

Erythrocytosis is a common reason for referral to hematology services and is usually secondary in origin. The aim of this study was to assess clinical characteristics and clonal hematopoiesis (CH) in individuals with erythrocytosis in the population-based Lifelines cohort (n = 147 167). Erythrocytosis was defined using strict (World Health Organization [WHO] 2008/British Committee for Standards in Hematology) and wide (WHO 2016) criteria. Read More

View Article and Full-Text PDF
December 2020

Postpartum vertebral artery dissection: case report and review of the literature.

Thromb J 2020 Oct 29;18(1):30. Epub 2020 Oct 29.

Department of Internal Medicine, University of Nevada, Reno School of Medicine, 1155 Mill Street, W-11, Reno, NV, 89052, USA.

Background: Hypertensive disorders of pregnancy are associated with vascular complications, including ischemic stroke and cervical artery dissection. Vertebral artery dissection (VAD), however, is rare. We describe a 31-year-old female who presented with vertigo, nausea, and vomiting and was found to have a VAD. Read More

View Article and Full-Text PDF
October 2020

Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.

Hematology Am Soc Hematol Educ Program 2020 12;2020(1):450-459

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN.

Myelodysplastic syndrome (MDS)/myeloproliferative neoplasm (MPN) overlap syndromes are uniquely classified neoplasms occurring in both children and adults. This category consists of 5 neoplastic subtypes: chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), BCR-ABL1-negative atypical chronic myeloid leukemia (aCML), MDS/MPN-ring sideroblasts and thrombocytosis (MDS/MPN-RS-T), and MDS/MPN-unclassifiable (U). Cytogenetic abnormalities and somatic copy number variations are uncommon; however, >90% patients harbor gene mutations. Read More

View Article and Full-Text PDF
December 2020

Endovascular Trapping of a Giant Splenic Artery Aneurysm by Liquid Embolic in a Case of EHPVO with Hypersplenism with a Complicated Post Procedure Course.

Ann Vasc Surg 2021 Apr 21;72:666.e1-666.e6. Epub 2020 Nov 21.

Department of Hematology & Bone Marrow transplant, Fortis Hospital and Cancer Institute, Bangalore, Karnataka, India.

Case of extrahepatic portovenous obstruction (EHPVO) with giant splenic artery aneurysm and concomitant hypersplenism. The presence of bicytopenia and venous collaterals around the giant splenic aneurysm made splenectomy risky, and endovascular trapping of the giant aneurysm with partial splenic embolization was planned. Due to high flow, intraprocedural crossing of the giant aneurysm was not possible, and large coils were unstable. Read More

View Article and Full-Text PDF

Austrian recommendations for the management of essential thrombocythemia.

Wien Klin Wochenschr 2021 Jan 19;133(1-2):52-61. Epub 2020 Nov 19.

Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University of Vienna, Vienna, Austria.

According to the World Health Organization (WHO) classification, essential (primary) thrombocythemia (ET) is one of several Bcr-Abl negative chronic myeloproliferative neoplasms (MPN). The classical term MPN covers the subcategories of MPN: ET, polycythemia vera (PV), primary myelofibrosis (PMF), and prefibrotic PMF (pPMF). ET is marked by clonal proliferation of hematopoietic stem cells, leading to a chronic overproduction of platelets. Read More

View Article and Full-Text PDF
January 2021

Bcor deficiency perturbs erythro-megakaryopoiesis and cooperates with Dnmt3a loss in acute erythroid leukemia onset in mice.

Leukemia 2020 Nov 6. Epub 2020 Nov 6.

Centro di Ricerca Emato-Oncologica (CREO), University of Perugia, Perugia, 06132, Italy.

Recurrent loss-of-function mutations of BCL6 co-repressor (BCOR) gene are found in about 4% of AML patients with normal karyotype and are associated with DNMT3a mutations and poor prognosis. Therefore, new anti-leukemia treatments and mouse models are needed for this combinatorial AML genotype. For this purpose, we first generated a Bcor knockout mouse model characterized by impaired erythroid development (macrocytosis and anemia) and enhanced thrombopoiesis, which are both features of myelodysplasia/myeloproliferative neoplasms. Read More

View Article and Full-Text PDF
November 2020

Ischemic and Bleeding Events Associated with Thrombocytopenia and Thrombocytosis after Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction.

J Clin Med 2020 Oct 21;9(10). Epub 2020 Oct 21.

Division of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea.

The early and late ischemic and bleeding clinical outcomes according to baseline platelet count after percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (AMI) remain unclear. Overall, 10,667 patients from the Cardiovascular Risk and identification of potential high-risk population in AMI (COREA-AMI) I and II registries were classified according to the following universal criteria on baseline platelet counts: (1) moderate to severe thrombocytopenia (platelet < 100 K/μL, = 101), (2) mild thrombocytopenia (platelet = 100~149 K/μL, = 631), (3) normal reference (platelet = 150~450 K/μL, = 9832), and (4) thrombocytosis (platelet > 450 K/μL, = 103). The primary endpoint was the occurrence of major adverse cardiovascular events (MACE). Read More

View Article and Full-Text PDF
October 2020

Recurrent arterial thrombosis of the lower extremity with secondary thrombocythemia due to reperfusion injury: a case report.

Ann Palliat Med 2020 Sep;9(5):3690-3697

Department of Vascular Surgery, the First Hospital of Hebei Medical University, Shijiazhuang, China.

Thrombocythemia is an important cause for thrombogenesis and can be classified as essential or secondary according to the etiology. Secondary thrombocythemia (ST), also called reactive thrombocytosis, is caused by a disorder that triggers increased production by normal platelet-forming cells and is characterized in terms of abnormal increased number of platelet in blood and megakaryocytes in bone marrow. Previous reports have found that complications from malignant tumors, chronic inflammation, acute inflammation, acute hemorrhage, spleen resection etc. Read More

View Article and Full-Text PDF
September 2020

Case Report: Adult Still's Disease in an Alemtuzumab-Treated Multiple Sclerosis Patient.

Front Immunol 2020 28;11:2099. Epub 2020 Aug 28.

Department of Neurology and Neurogeriatrics, Johannes-Wesling-Hospital Minden, University Hospital Ruhr University of Bochum, Minden, Germany.

Background: Autoimmune adverse events are the most relevant risks of alemtuzumab therapy. We present a patient with relapsing-remitting multiple sclerosis, who developed adult-onset Still's disease (AOSD) following alemtuzumab treatment.

Case Presentation: The patient suffered from sore throat, swallowing difficulties, high spiking quotidian fever, generalized skin rash, arthritis, and myalgia 2 months after the second course of alemtuzumab. Read More

View Article and Full-Text PDF

Polycystic kidney disease concurrent with feline parvovirus and bacterial infections in domestic shorthair cat: a case report.

Comp Clin Path 2020 Sep 28:1-5. Epub 2020 Sep 28.

Department of Clinical Studies, Faculty of Veterinary Medicine, Universiti Malaysia Kelantan, Pengkalan Chepa, 16100 Kota Bharu, Kelantan Malaysia.

Feline polycystic kidney disease (PKD) is an inherited disorder caused by the mutation of PKD1 gene that eventually lead to the development of chronic kidney disease. The latter condition causes hypertension and eventually progress into congestive heart failure. Feline parvovirus (FPV) is a highly contagious and often fatal disease infecting cats and other members of Felidae. Read More

View Article and Full-Text PDF
September 2020

Extreme thrombocytosis is associated with critical illness and young age, but not increased thrombotic risk, in hospitalized pediatric patients.

J Thromb Haemost 2020 12 21;18(12):3352-3358. Epub 2020 Oct 21.

Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.

Background: Extreme thrombocytosis (EXT, platelet count > 1000 × 10 /μL) is an uncommon but potentially clinically significant finding. Primary EXT in the setting of myeloproliferative disorders is linked to thrombotic and/or bleeding complications more frequently than secondary EXT, which typically occurs in reaction to infection, inflammation, or iron deficiency. However, comorbidities have been reported in adults with secondary EXT. Read More

View Article and Full-Text PDF
December 2020

Triple-Negative Essential Thrombocythemia Complicated by Thrombosis and Acquired von Willebrand Disease in a Young Man.

Am J Case Rep 2020 Aug 23;21:e924560. Epub 2020 Aug 23.

Department of Hematology/Oncology, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Camp Hill, PA, USA.

BACKGROUND Essential thrombocythemia (ET) is a type of myeloproliferative neoplasm (MPN) characterized by sustained thrombocytosis in peripheral blood. Patients typically have gene mutations like JAK2V617F, CALR, and MPLW515L/K. This report describes a young man with ET without any of the above mutations who had paradoxical bleeding due to acquired Von-Willebrand disease. Read More

View Article and Full-Text PDF

Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study.

Blood 2020 12;136(26):3056-3061

Department of Internal Medicine, National Reference Center for Immune Cytopenias, Henri Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris-Est Creteil, Créteil, France.

Management of immune thrombocytopenia (ITP) during pregnancy can be challenging because treatment choices are limited. Thrombopoietin receptor agonists (Tpo-RAs), which likely cross the placenta, are not recommended during pregnancy. To better assess the safety and efficacy of off-label use of Tpo-RAs during pregnancy, a multicenter observational and retrospective study was conducted. Read More

View Article and Full-Text PDF
December 2020

Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis.

Intern Med 2020 15;59(16):1947-1956. Epub 2020 Aug 15.

Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Japan.

Objective Little information is available about the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) for patients with secondary myelofibrosis from essential thrombocythemia (ET) and polycythemia vera (PV). A nationwide retrospective study of the outcome of HSCT for post-ET and post-PV myelofibrosis was conducted in Japan. Patients and Methods Clinical data for patients with post-ET (n=29) and post-PV (n=9) myelofibrosis who had received first allogeneic HSCT were extracted from the Transplant Registry Unified Management Program, which is a registry of the outcomes of HSCT in Japan. Read More

View Article and Full-Text PDF
January 2021

Screening for Occult Cancer in Patients with Venous Thromboembolism: Past, Present, and Future.

Hamostaseologie 2020 Aug 29;40(3):270-279. Epub 2020 Jul 29.

Department of Pneumonology, Medical Surgical Unit of Respiratory Diseases, Instituto de Biomedicina de Sevilla (IBiS), Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Hospital Universitario Virgen del Rocío, Seville, Spain.

A strong link between cancer and thrombosis has been well recognized. The occurrence of venous thromboembolism (VTE) can be the first clinical sign of an undiagnosed (i.e. Read More

View Article and Full-Text PDF

Prevalence and risk factors of high echocardiographic probability of pulmonary hypertension in myeloproliferative neoplasms patients.

Int J Hematol 2020 Nov 23;112(5):631-639. Epub 2020 Jul 23.

Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, 110 Inthawaroros Street, Muang, Chiang Mai, 50200, Thailand.

Pulmonary hypertension (PH) is emerging as a complication of myeloproliferative neoplasms (MPNs). This was a prospective study conducted at Chiang Mai University Hospital. The primary objective was to determine the prevalence of high echocardiographic probability of PH in MPNs patients. Read More

View Article and Full-Text PDF
November 2020

Atypical Myocardial Infarction with Apical Thrombus and Systemic Embolism: A Rare Presentation of Likely JAK2 V617F-Positive Myeloproliferative Neoplasm.

Case Rep Oncol Med 2020 19;2020:9654048. Epub 2020 May 19.

Richmond University Medical Center, USA.

A few types of myeloproliferative neoplasms may be significant for Janus-associated kinase 2 mutation, JAK2 V617F, including polycythemia vera, essential thrombocythemia, and primary myelofibrosis. The prevalence of JAK2 mutation is low in the general population but higher in patients with myeloproliferative neoplasms. Some patients with JAK2 V617F-positive essential thrombocythemia are asymptomatic, but others may develop hemorrhagic or thromboembolic complications. Read More

View Article and Full-Text PDF

Atypical polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes syndrome without polyneuropathy: A case report.

Medicine (Baltimore) 2020 Jul;99(27):e20812

Department of Neurology.

Introduction: Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes (POEMS) syndrome is a rare paraneoplastic syndrome that occurs secondary to an underlying plasma cell disorder. The diagnosis of POEMS syndrome is 2 of the mandatory major criteria (polyneuropathy and monoclonal plasma cell disorder), 1 of the other major criteria (Castleman's disease, sclerotic bone lesions, or vascular endothelial growth factor elevation), and at least 1 of the minor criteria (organomegaly, extravascular volume overload, endocrinopathy, skin changes, papilledema, thrombocytosis, or polycythemia). However, some cases do not fully meet the diagnostic criteria, such cases are referred to as incomplete or atypical POEMS syndrome. Read More

View Article and Full-Text PDF